Table of Contents Author Guidelines Submit a Manuscript
Volume 2006, Article ID 39130, 3 pages
Case Report

Primary Cardiac Angiosarcoma

1Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware St SE, Minneapolis, MN 55455, USA
2Division of Hematology/Oncology, Worcester Medical Center, Fallon Clinic, Worcester, MA 01608, USA

Received 31 May 2005; Revised 4 June 2006; Accepted 8 June 2006

Copyright © 2006 Dhatri Kodali and Kala Seetharaman. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Primary cardiac sarcoma is a rare clinical entity, with an incidence of 0.0001% in collected autopsy series. The majority of the literature describes a uniformly dismal prognosis with a median survival of only 6 months for these aggressive tumors. Standard surgery, adjuvant chemotherapy, and radiotherapy have been consistently unsuccessful. Early heart transplantation and novel radiation therapy approaches may offer a survival benefit in nonmetastatic tumors, but up to 80% of the patients present with systemic metastasis at diagnosis. Though several chemotherapeutic regimens have been tried, the role of chemotherapy is not well established and outcome data available is minimal. Liposomal doxorubicin (PLD) has been shown to be useful in the treatment of soft tissue sarcomas, and our case supports its use in cardiac angiosarcoma.